Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Earning Call

OmniAb Shares Jump 14% in 10 Days Since Earnings Call

OmniAb Raises 2026 Revenue Guidance to $39 Million After Eli Lilly Partnership

+14.74% in 10 days $4.75 when we broke this story → $5.45 peak on 9 Nov 2026

OmniAb reported a significant increase in third-quarter revenue and adjusted its full-year financial outlook upward for the fourth time this year. The company is benefiting from a new partnership with Eli Lilly and a substantial backlog of contracted milestone payments.

Doctor, researcher, laboratory, coronavirus. Stock photo illustrating OmniAb's earning call story.
OmniAb, Inc. · Photo: Elf-Moondance / Pixabay

Key highlights

  • Revenue for the third quarter of 2026 grew to $4 million from $2.2 million in the prior-year period
  • Management raised full-year 2026 revenue guidance to a range of $35 million to $39 million
  • Contracted potential milestone payments across active partner programs now exceed $3 billion
  • Year-to-date revenue reached $31.8 million through September 30, 2026
  • Cash and cash equivalents guidance for year-end 2026 was increased to a range of $53 million to $57 million
  • A major partnership was established with Eli Lilly to utilize OmniAb antibody discovery technologies

Financial Performance

OmniAb delivered a third-quarter revenue of $4 million, marking an increase from the $2.2 million reported in the third quarter of 2025. This performance contributed to a year-to-date revenue total of $31.8 million. The revenue growth was primarily driven by the achievement of technical and clinical milestones within the company's partner portfolio. Alongside the revenue gains, management updated its liquidity outlook, now projecting year-end cash and cash equivalents to fall between $53 million and $57 million, an increase from previous estimates.

OmniAb, Inc. share price · last month
Line chart of OmniAb, Inc.'s share price over the last month, from $4.69 on 19 Oct → $4.89 on 16 Nov; our story on 30 Oct at $4.75.

Up 2.9% since our story on 30 Oct: $4.75 when we broke it → $4.89 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$4.69
20 Oct$4.96
21 Oct$4.92
22 Oct$4.78
23 Oct$4.66
26 Oct$4.61
27 Oct$4.96
28 Oct$5.28
29 Oct$5.23
30 Oct$5.11
2 Nov$5.09
3 Nov$5.15
4 Nov$5.18
5 Nov$4.83
6 Nov$5.03
9 Nov$5.30
10 Nov$5.10
11 Nov$5.10
12 Nov$4.95
13 Nov$4.91
16 Nov$4.89

Management Outlook

The company has demonstrated a consistent trend of upward revisions to its 2026 financial targets. Beginning the year with a revenue guidance range of $25 million to $30 million in March, the forecast was incrementally raised to $28 million to $33 million in May, then to $32 million to $36 million in August, and finally to the current range of $35 million to $39 million. Looking further ahead, management expressed expectations for exploration revenue to double in 2027 as the partnership pipeline matures and discovery activities scale.

Business Overview

OmniAb operates as a biotechnology platform provider, offering pharmaceutical partners access to a diverse array of transgenic animals and high-throughput screening technologies for antibody discovery. The business model relies on a combination of upfront license fees, research funding, and downstream milestone and royalty payments. As of late 2026, the company maintains a robust portfolio of active programs with a total contracted potential milestone value exceeding $3 billion.

Sector Dynamics

In the broader biotechnology sector, platform companies are increasingly evaluated on their ability to secure high-value partnerships with major pharmaceutical entities. The recent collaboration between OmniAb and Eli Lilly serves as a focal point for the company's current discovery efforts. Analysts on the call focused on the nuances of royalty structures, particularly regarding Baticlimab, and the sustainability of pull-through rates for exploration consumables in the current clinical research environment.

What to Watch

  • Primary completion results for up to 19 partner-led clinical trials scheduled through late 2026 and 2027
  • Updates on the pull-through rates for exploration consumables and their impact on 2027 revenue growth
  • Management presentations at several upcoming investor conferences scheduled for November 2026
  • Clarity on royalty pricing and commercialization milestones for the Baticlimab program
  • The impact of the Eli Lilly partnership on the company's short-term milestone realization
Recent quarters and guidance
DateAnnouncementAmount
06 Aug 2026Q2 2026 revenue; raised FY 2026 revenue guidance to $32M–$36MSource: stocktitan.net$13.4 Million
07 May 2026Q1 2026 revenue; raised FY 2026 revenue guidance to $28M–$33MSource: SEC filing$14.4 Million
04 Mar 2026Q4 2025 revenue; introduced FY 2026 revenue guidance of $25M–$30MSource: investors.omniab.com$8.4 Million
04 Nov 2025Q3 2025 revenue; lowered FY 2025 revenue guidance to $18M–$22MSource: investors.omniab.com$2.2 Million
06 Aug 2025Q2 2025 revenue; affirmed FY 2025 revenue guidance of $20M–$25MSource: investors.omniab.com$3.9 Million
OmniAb, Inc. · financial snapshot
Share price$4.75
Market cap$691M
Revenue (annual)$19M
1-month price change-4.23%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by OmniAb, Inc. announcing third quarter 2026 financial results and updated 2026 guidance.

Read the filing ↗

Track OmniAb, Inc. live

Get the next OmniAb, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.